Determining the Direct and Indirect Healthcare and Social Costs For Diabetic Retinopathy Management. A Systematic Review.

Author:

BENHAMZA MAWDDA1,Dahlui Prof. Maznah1,Ayu Prof. Mas1

Affiliation:

1. University of Malaya, Social and Prevetive Medcine. Faculty of Medicine

Abstract

Abstract Diabetic retinopathy is a rapidly growing a global public health threat; it affects 1 in 3 people with diabetes and is still the leading cause of blindness among the working- age population. The management of diabetic retinopathy is becoming more advanced and effective but is highly expensive compared to other ocular diseases. Aim: To report direct medical, indirect medical and nonmedical costs of diabetic retinopathy in developed and developing countries through a systematic review. Methods: Related articles published in the PubMed, Google Scholar, and EMBASE electronic databases from 1985 to 2022 were identified using the key words direct medical and indirect medical and social costs of diabetic retinopathy. However, previous systematic reviews, abstracts, and case reports were excluded. Results: Only12 articles were eligible for the assessment of the economic burden of diabetes management and its complications. In Germany, the average cost from a social perspective was US$1,361.35 per patient and the average cost of DR from the GKV perspective was US$865.450 per patient in 2002. In India, the average annual direct cost was estimated to be US$19,089.072 and the indirect cost was US$105,857.136 in 2016. Discussion: Increasing the prevalence of DR leads to increased direct and indirect healthcare expenditures, in addition, increasing the severity of DR leads to increased expenditure as well. The most significant concern about DR is that it affects working age adults with irreversible blindness, especially in advanced stages. While the management and control are available and inexpensive. Conclusion: The enormous financial burden associated with DR expenses should be reconsidered, and the current screening and management programs should be revised to improve the quality and reduce the cost that is associated with DR to achieve the Sustainable Development Goal SDG (3), which ensures good health and well-being.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3